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Amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD) constitutes a
devastating disease spectrum characterised by TDP-43 pathology. 
Understanding how TDP-43 contributes to neurodegeneration will help direct
therapeutic efforts. Here, we have created a novel TDP-43 knock-in mouse with
a human-equivalent mutation in the endogenous mouse Tardbp gene. TDP-
43Q331K mice demonstrate cognitive dysfunction and a paucity of parvalbumin
interneurons. Critically, TDP-43 autoregulation is perturbed leading to a gain of 
TDP-43 function, and altered splicing of Mapt, another pivotal dementia gene. 
Furthermore, a novel approach to stratify transcriptomic data by phenotype in
differentially affected mutant mice reveals 471 changes linked with improved 
behaviour. These changes include downregulation of two known modifiers of 
neurodegeneration, Atxn2 and Arid4a, and upregulation of myelination and 
translation genes. With one base change in murine Tardbp, this study identifies
TDP-43 misregulation as a pathogenic mechanism that may underpin ALS-FTD, 
and exploits phenotypic heterogeneity to yield candidate suppressors of 
neurodegenerative disease.
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are 
destructive neurodegenerative diseases that exist on a clinicopathological spectrum
(ALS-FTD)1. ALS is characterised by motor impairment and FTD by executive 
dysfunction, language impairment and behavioural changes. Nearly all cases of ALS,
half of FTD cases, and most hereditary forms of ALS and FTD are characterised by 
cytoplasmic mislocalisation and aggregation of the 43kDa TAR DNA-binding protein 
(TDP-43)2,3. Significantly, the identification of mutations in the gene encoding TDP-43 
(TARDBP) as a cause of ALS and FTD confirmed that TDP-43 plays a mechanistic 
role in neurodegeneration4,5. This role remains undefined. 
3TDP-43 is a conserved RNA-binding protein with critical roles in splicing in the 
nervous system6. TDP-43 also demonstrates exquisite autoregulation by binding to its 
transcript, triggering alternative splicing of intron 7 within the TARDBP 3’-untranslated 
region (UTR) and destruction of its mRNA7. Experimentally increasing or decreasing
TDP-43 levels both cause neuronal loss, but whether human neurodegeneration is 
caused by a gain or loss of TDP-43 function remains unclear. Modelling of mutant 
TDP-43 in vivo has relied on variable degrees of transgenic overexpression of TDP-
43 to replicate pathological changes seen in post-mortem human tissues8. However, 
TDP-43 transgenic mouse models have demonstrated that TDP-43 aggregation is not 
necessary to cause neurodegeneration9, and whether TDP-43 aggregation is causally 
linked to disease onset is unclear.
A caveat of transgenic TDP-43 mouse models is that phenotypes may partly be 
artefacts of overexpression. Furthermore, the cell-type specific expression of single 
TDP-43 splice forms in transgenic models using neuronal promoters, and temporally-
triggered expression of transgenes in adulthood do not reflect ubiquitous expression 
and alternative splicing of Tardbp, including during embryonic development10. To 
unravel the role of mutant TDP-43 in the disease pathogenesis we created a knock-in 
mouse harbouring only a human-equivalent point mutation in the endogenous mouse 
Tardbp gene. This model replicates the human mutant state as closely as possible, 
retaining the endogenous gene structure including promoters and autoregulatory
3’UTR, and maintaining the ubiquitous expression of TDP-43 during embryonic 
development and in adulthood. By avoiding deliberate manipulation of TDP-43
expression, this model helps elucidate both mediators and modifiers of cognitive 
dysfunction in ALS-FTD. 
Results
TDP-43Q331K causes behavioural phenotypes and disproportionately affects male
4mice
Over 50 TARDBP mutations at conserved sites have been identified in ALS-FTD11. 
We chose to introduce the n.991C>A (p.Q331K) mutation into murine Tardbp
because TDP-43Q331K is a particularly toxic species in vitro and in vivo4,9,12,13. 
Mutagenesis was performed using CRISPR/CAS9 methodology yielding four 
founders with the Q331K mutation (Fig. 1a). Mutagenesis events at predicted off-
target regions and in the remainder of Tardbp were excluded by Sanger sequencing. 
Founder #52 was outcrossed to F4 to remove other potential off-target mutagenesis 
events. Heterozygous (TDP-43Q331K/+) F4 animals were intercrossed to generate 
mutant and wild-type mice. Homozygotes (TDP-43Q331K/Q331K) were viable (Fig. 1b, 
Supplementary Fig. 1a) and appeared superficially normal as juveniles. Since TDP-
43 transgenic mice have not been shown to rescue TDP-43 knockout mice, TDP-
43Q331K/Q331K knock-in mice represent a unique opportunity to study mutant TDP-43 in 
vivo in the absence of wild-type TDP-43.
We initially screened for phenotypes in a small group of wild-type and TDP-
43Q331K/Q331K mice using automated continuous behavioural monitoring (ACBM)14. At 
~4 months of age TDP-43Q331K/Q331K male and female mice demonstrated reduced 
walking and hanging, and increased rearing and eating-by-hand, but no alterations in 
circadian rhythmicity (Fig. 1c). The most consistent phenotype was reduced walking
in males (Fig. 1d and Supplementary Fig. 1b). Further breeding revealed an under 
representation of male mutants, yet females were present at Mendelian ratios, further 
suggesting that males are more susceptible to deleterious effects of TDP-43Q331K
(Fig. 1e). This is notable as sporadic ALS is more common in men, and TDP-43 
mutations demonstrate greater penetrance in men than women15. We therefore 
focussed on males in subsequent studies, breeding two cohorts of mice: Cohort 1 for 
5motor, pathological and transcriptomic studies; Cohort 2 for cognitive studies. 
TDP-43Q331K mice demonstrate no significant motor impairment, weight gain due 
to hyperphagia, and transcriptomic changes in spinal motor neurons
To identify ALS-like motor deficits we measured Rotarod performance in Cohort 1
mice. From ~6 months of age TDP-43Q331K/+ and TDP-43Q331K/Q331K mice demonstrated
reduced Rotarod latencies (Fig. 2a). Interestingly, mutants demonstrated 
hyperphagia, a feature of FTD16, and gained more weight than wild-types (Fig. 2b,c). 
Increased weight could contribute to impaired Rotarod performance, so we tested 
Cohort 2 mice, which were weight-matched due to dietary control (Supplementary
Fig. 2a). Weight-matched mutants performed similarly to wild-types up to 16 months 
of age (Fig. 2d), suggesting that mutant mice do not have significant impairment of 
motor coordination.
To determine if mutant mice demonstrated lower motor neuron degeneration we 
examined spinal cords from 5-month-old mice to identify early pathological changes. 
Motor neurons demonstrated normal morphology and numbers with no TDP-43 
aggregation or mislocalisation in TDP-43Q331K/Q331K mice (Fig. 2e,f Supplementary 
Fig. 2b). Quantification of neuromuscular junctions (NMJs) and succinate 
dehydrogenase staining in gastrocnemius muscles were normal in TDP-43Q331K/Q331K 
mice, suggesting no significant denervation (Supplementary Fig. 2c,d,f). 
Examination of 18 to 23-month-old mice similarly found no evidence of denervation
(Supplementary Fig. 2e) and no electrophysiological evidence of motor unit loss
(Fig. 2g, Supplementary Fig. 2g-o). 
Collectively, these data indicated a remarkable resilience of neuromuscular units to 
TDP-43Q331K. We hypothesised that gene expression changes occurring in motor 
6neurons of mutant mice could elucidate how these cells respond to cellular stress 
caused by TDP-43Q331K. We isolated RNA from laser-captured lumbar motor neurons
from 5-month-old mice and performed RNASeq (Supplementary Fig. 3a,b). This 
yielded 31 significant expression and splicing differences between wild-type and TDP-
43Q331K/Q331K mice (Fig. 2h,i Supplementary Fig. 3c-e, Supplementary Table. 1). A 
notable change was upregulation of Agrin. Agrin is secreted by neurons and 
functions through muscle specific kinase to cluster acetylcholine receptors at NMJs17. 
Agrin upregulation may therefore promote NMJ function in TDP-43Q331K/Q331K mice. 
Interestingly, the largest gene expression change was a three-fold increase in 
expression of aldehyde oxidase 1 (Aox1). Little is known about the neurobiological 
functions of AOX1 although its transcript has been observed in the anterior horn of 
the spinal cord18. AOX1 catalyses the conversion of retinaldehyde to retinoic acid 
(RA)19, which functions in neuronal maintenance in the adult nervous system and 
following axon injury. Thus, Aox1 upregulation may benefit motor neurons in TDP-
43Q331K/Q331K mice. Immunostaining revealed expression of AOX1 in spinal motor 
neurons (Fig. 2j), but no difference in expression between TDP-43Q331K/Q331K and wild-
type mice (Fig. 2k, Supplementary Fig. 3f). This could be because upregulated 
AOX1 is transported into peripheral motor axons, as we found abundant expression
of AOX1 in motor axons (Fig. 2k).
TDP-43Q331K mice display executive dysfunction, memory impairment and 
phenotypic heterogeneity
In parallel with motor studies, to determine if TDP-43Q331K causes FTD-like cognitive 
dysfunction we performed neuropsychological assessments on Cohort 2 mice using 
touchscreen operant technology. To test if mice exhibited FTD-related deficits we 
conducted the 5-choice serial reaction time task (5-CSRTT; Fig. 3a), which measures
frontal/executive function including attention, perseveration, impulsivity, and 
7psychomotor speed22. At 4 months of age the number of training sessions required to 
reach performance criteria for probe testing was higher in TDP-43Q331K/Q331K mice than 
wild-types (Fig. 3b), indicating learning deficits in mutants. Following training, animals 
underwent probe testing at 6 and 12 months of age. Accuracy (Fig. 3c,d insets) and 
omission percentage were comparable between genotypes at 6 months of age (Fig. 
3c). However, at 12 months of age, while accuracy remained normal, omission
percentage was greater in TDP-43Q331K/+ and TDP-43Q331K/Q331K mice (Fig. 3d), 
suggesting attentional deficits and cognitive decline in mutants. Reward collection 
and response latencies, and premature and perseverative response rates were 
similar between genotypes (Supplementary Fig. 4a-h), arguing against visual, 
motivational, or significant motor deficits as causes for increased omissions. We also 
measured motivation using fixed (FR) and progressive-ratio (PR) schedules. No 
significant differences were found between genotypes, further suggesting that 
increased omissions in mutants were not due to motivational deficits (Fig. 3e,f). 
Collectively, these data indicate an inattention phenotype in TDP-43Q331K/+ and TDP-
43Q331K/Q331K mice, which is consistent with frontal/executive dysfunction. 
Next, to explore temporal lobe-dependent function, we conducted the spontaneous 
object recognition task, a test of declarative memory. Initial exploratory times did not 
differ between genotypes (Fig. 3g), but in the choice phase a deficit emerged in TDP-
43Q331K/+ and TDP-43Q331K/Q331K mice (Fig. 3h), indicating memory impairment. The 
combination of executive dysfunction and memory impairment, together with 
hyperphagia in free-fed Cohort 1 mice led us to conclude that TDP-43Q331K/+ and TDP-
43Q331K/Q331K mice recapitulate FTD at the behavioural level. 
8During touchscreen analyses we noted that some Cohort 2 mutant mice 
demonstrated consistently worse performance than other mutants (Fig. 3b, 
Supplementary Fig. 4i). This phenotypic heterogeneity was intriguing given that the 
mutant mice were genetically homogeneous. Furthermore, ALS-FTD is a remarkably
heterogeneous disease in which patients display varying phenotypic severity and 
different rates of disease progression. Indeed, TARDBP mutation carriers 
demonstrate variable penetrance even with homozygous mutations15. We therefore 
looked for further evidence of phenotypic heterogeneity by examining Cohort 1 mice 
using the marble-burying assay, a measure of innate digging behaviour23. From 5 to 
18 months of age, wild-type mice buried ~80% of marbles. Mutants demonstrated a 
range of digging behaviours, with some animals behaving similarly to wild-types, but 
others demonstrating attenuated digging behaviour (Fig. 3i, Supplementary Fig. 4j). 
These observations confirm the presence of phenotypic heterogeneity in genetically 
homogeneous groups of mutant mice, and suggest that some mutants were relatively 
resistant to behavioural deficits caused by TDP-43Q331K.
TDP-43Q331K/Q331K mice demonstrate perturbed TDP-43 autoregulation and 
reduced parvalbumin-positive neurons
To obtain mechanistic insight into the cognitive dysfunction caused by TDP-43Q331K
we sacrificed 5-month-old mice for pathological and transcriptomic studies. Prior to 
sacrifice we performed the marble-burying assay to identify animals with a range of 
different behaviours (Fig. 4a). Analysis of frontal cortices from wild-type and TDP-
43Q331K/Q331K mice demonstrated no significant reduction in cortical thickness or 
cellular density in mutants (Fig. 4b, Supplementary Fig. 5a-c), and no nuclear 
clearing or cytoplasmic aggregation of TDP-43 (Fig. 4c). However, subcellular 
fractionation and immunoblotting demonstrated a ~45% increase in nuclear TDP-43 
in TDP-43Q331K/Q331K compared to wild-type mice (Fig. 4d,e, Supplementary Fig. 5d). 
9TDP-43 has critical roles in RNA processing, which may be disturbed in disease. We 
therefore performed transcriptomic analyses using RNASeq of frontal cortices from
six wild-type, six TDP-43Q331K/+, and eight TDP-43Q331K/Q331K mice (Supplementary Fig 
6a). We identified 171 genes that were upregulated and 233 that were
downregulated in TDP-43Q331K/Q331K mice relative to wild-type (Fig. 4f,g). TDP-43Q331K/+
mice demonstrated changes that trended in the same direction as TDP-43Q331K/Q331K
mice, suggesting a dose-dependent effect of the mutation. In particular, we noted a 
14% increase in expression of Tardbp in TDP-43Q331K/Q331K mice (Fig. 4h). As nuclear 
TDP-43 protein expression was also raised in mutants, we conclude that the Q331K 
mutation disturbs TDP-43 autoregulation. 
One notable gene that was downregulated in mutant mice was Nek1. This change is
consistent with human data indicating that loss-of-function mutations in NEK1 cause 
ALS24,25. Another downregulated gene was Pvalb, which encodes the calcium 
buffering protein parvalbumin. Reduced parvalbumin immunopositivity is observed in 
patients with ALS and is linked with selective cellular vulnerability in ALS26. We 
therefore immunostained for parvalbumin and found a ~25% reduction in parvalbumin-
positive cells in the frontal cortex of TDP-43Q331K/Q331K mice (Fig. 4i,j). Co-staining for 
TDP-43 in this affected subset of cortical neurons did not demonstrate TDP-43 
mislocalisation (Fig. 4k,l). Notably, fast-spiking parvalbumin interneurons are 
GABAergic inhibitory cells that play a direct role in the control of attention27. We 
therefore conclude that a paucity of parvalbumin interneurons may be responsible for 
the attentional impairment of TDP-43Q331K/Q331K mice. 
Splicing analysis indicates a gain-of-function of TDP-43Q331K and links aberrant 
TDP-43 homeostasis with altered splicing of Mapt
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TDP-43 plays key roles in alternative splicing. We therefore interrogated the cortical 
transcriptomic dataset further for splicing differences between mutant and wild-type 
mice and identified 138 splicing changes in 106 genes (Fig. 5a,b, Supplementary
Fig. 6b). This included an ~80% increase in retention of Tardbp intron 7 in TDP-
43Q331K/Q331K mice (Fig. 5c,d), which will promote the production of stable mRNA 
species7. This confirms that TDP-43 autoregulation is perturbed in mutant mice.
Another prominent change was a 2.4-fold increase in exclusion of Sort1 exon 17b, a 
known splicing target of TDP-43 (Fig. 5e,f). This change is consistent with a gain of 
function of TDP-4328. 
We also noted altered splicing of exons 2 and 3 of Mapt, which encodes the 
microtubule associated protein tau and is mutated in FTD with Parkinsonism29. We 
detected increased inclusion of Mapt exons 2 and 3 in TDP-43Q31K/Q331K mice (Fig. 5g-
i). This is notable as inclusion of exons 2 and 3 of Mapt is associated with increased 
somatodendritic localization and aggregation of tau30. We immunostained wild-type 
and mutant frontal cortices for total tau but found no difference in the localization or 
aggregation of tau (Supplementary Fig. 6c). Analysis of iCLIP databases
(http://icount.biolab.si/groups.html) revealed that TDP-43 binds to an intronic
sequence upstream of Mapt exon 2 (Fig. 5g). This confirmed that Mapt exons 2 and 
3 are likely splicing targets of TDP-43. The identification of this novel splicing effect of 
TDP-43 on Mapt mechanistically links these two major dementia genes.
Next, to determine if TDP-43 misregulation could be responsible for temporal lobe-
dependent functions we analysed hippocampal RNA extracts from male mice. We 
also examined hippocampi from female mice to determine if TDP-43 misregulation
was restricted to male mice. Splicing analyses for Tardbp, Sort1 and Mapt were 
consistent with a gain of function of TDP-43 in mutant mice of both genders (Fig. 
5j,k). This indicates that TDP-43 misregulation occurs beyond the frontal cortex, and 
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in both male and female mice.
Finally, to confirm that our behavioural and transcriptomic observations were caused 
by mutant TDP-43 and not off-target CRISPR mutagenesis effects we performed the 
marble-burying assay in a second line of Tardbp Q331K knock-in mice, line #3, and 
found a similar impairment of digging behavior to line #52 mice (Supplementary Fig. 
6d). We also analysed RNA from line #3 mice and observed an increase in Tardbp
expression and altered splicing of Tardbp and Sort1, which is consistent with 
perturbed autoregulation and a gain of function of TDP-43 (Supplementary Fig. 6e).
Furthermore, line #3 TDP-43Q331K/Q331K mice also demonstrated increased inclusion of 
exons 2 and 3 of Mapt, and a paucity of parvalbumin-positive neurons relative to wild-
type mice, replicating key splicing and pathological observations made in line #52 
mice (Supplementary Fig. 6e,f), 
TDP-43 misregulation in lumbar spinal cords of mutant mice further implicates 
interneurons in ALS-FTD pathogenesis
Our transcriptomic profiling of frontal cortices and hippocampi elucidated a gain of 
function of TDP-43 in the brains of mutant mice. By contrast, spinal motor neurons
from mutants did not demonstrate TDP-43 misregulation as Tardbp, Sort1 and Mapt
were not differentially expressed or spliced in these cells (Fig. 6b). However, TDP-43 
misregulation could occur in other cells of the spinal cord, namely glia or 
interneurons. We therefore analysed RNA from homogenates of lumbar spinal cord
from the mice from which we had laser captured spinal motor neurons (Fig. 6a). 
Interestingly, spinal cord homogenates demonstrated increased expression of 
Tardbp, and altered splicing of Tardbp and Sort1 consistent with a gain of function of 
TDP-43 in mutant mice (Fig. 6c). Furthermore, spinal cords from mutant mice also 
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demonstrated increased inclusion of Mapt exon 2 (Fig. 6d). Given that Mapt
expression is predominantly neuronal rather than glial this suggests that a gain of 
TDP-43 function occurs in interneurons of the spinal cord.
Stratification of transcriptomic data from TDP-43Q331K/Q331K mice by phenotype 
identifies novel expression and splicing changes
As stated earlier, some mutant mice appeared relatively resistant to the cognitive 
effects of the Q331K mutation. We wished to exploit this phenotypic heterogeneity in 
TDP-43Q331K/Q331K mice to identify potential modifiers of cognitive dysfunction. For this 
purpose we divided the frontal cortical transcriptomic data from the eight TDP-
43Q331K/Q331K mice into two subsets according to their antemortem marble-burying 
behaviour. We designated this the ‘MB+/-’ comparison. TDP-43Q331K/Q331K mice that 
dug consistently well were designated MB+, and those that dug consistently poorly
were designated MB- (Fig. 7a,b). We hypothesised that transcriptomic differences 
between these two genotypically homogeneous groups would indicate molecular 
pathways that influenced the risk of developing cognitive impairment. Using this 
strategy we found 410 gene-expression and 61 splicing differences between MB+ 
and MB- groups (Fig. 7c, Supplementary Fig. 6g,h), which were entirely different to 
those seen in the earlier comparison with wild-type mice when all eight TDP-
43Q331K/Q331K mice were considered as one group (Fig. 4g, 5b). Interestingly, for 78% 
of these genes MB+ and MB- mice demonstrated opposing expression changes 
relative to wild-type (Fig. 7c, Supplementary Table 2 and MB+/- sections in
Supplementary Table. 1). Effectively, for these genes an expression change in one 
direction is associated with a poor behavioural phenotype, yet an expression change 
in the opposite direction is associated with improved behavior. Furthermore, there 
was no difference in TDP-43 expression or the degree of TDP-43 gain of function as 
evidenced by Sort1 splicing between MB+ and MB- groups. Taken together, these 
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data indicate that the MB+/- comparison genes could be metastable modulators of 
TDP-43-mediated cognitive dysfunction.
Significantly, two of the genes from the MB+/- comparison have previously been 
linked with suppression of neurodegeneration: Atxn2 and Arid4a. Compared to wild-
type mice, MB+ mice demonstrated reduced Atxn2 expression, while MB- mice 
demonstrated increased Atxn2 expression. This is in keeping with previous 
observations that Atxn2 knockdown suppresses TDP-43 toxicity in yeast, Drosophila
and mouse31,32. Furthermore, intermediate expansions of Atxn2 CAG repeat length is 
associated with ALS disease risk in humans31. Similarly, reduced expression of the 
chromatin-modeling gene Arid4a in MB+ mice is notable, as we previously found that 
loss of function mutations in hat-trick, the Drosophila orthologue of Arid4a, suppress 
TDP-43-mediated neurodegeneration in flies12. It is therefore likely that reduced 
levels of Atxn2 and Arid4a are similarly neuroprotective in TDP-43Q331K/Q331K MB+ 
mice. 
To identify the most significant pathways linked with phenotypic heterogeneity in the 
MB+/- comparison we cross-referenced the differential gene expression list with the 
Gene Ontology database for biological processes (Fig. 7c). Genes downregulated in 
MB+ mice were enriched for biological processes involving transcription, DNA 
methylation and chromatin modification. Genes upregulated in MB+ mice were 
enriched for processes involving protein translation and myelination, including the 
myelin repair gene Olig1, and Mbp, which encodes myelin basic protein
(Supplementary Table 2). Furthermore, examination of the splicing gene list also 
identified Mbp as a candidate (Fig. 7d,e). Specifically, MB- mice demonstrated a 
significantly increased expression of a specific splice form, which is predicted to 
encode Golli-Mbp, in which three additional exons upstream of classical Mbp are 
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normally expressed in non-myelinating cells including neurons, and in immature 
oligodendrocytes33. Collectively, this Gene Ontology analysis identifies an association 
between the upregulation of protein translation and oligodendrocyte genes and 
improved behaviour in TDP-43Q331K/Q331K mice, and suggests that the promotion of 
myelin repair pathways by oligodendrocytes in a mature state contributes to improved 
cognition.
To confirm the validity of MB+/- hits we deliberately swapped data from the worst 
performing MB+ mouse with that of the best performing MB- mouse. This resulted in 
all transcriptomic hits disappearing from the analysis (Fig. 7f). We also compared 
only the three best performing MB+ mice with the three worst performing MB- mice 
and found a diminished hit list, but which largely overlapped with the genes from the 
complete MB+/- comparison. Furthermore, we found two TDP-43Q331K/Q331K mice that 
were littermates yet demonstrated contrasting digging behaviour on repeated 
assessment (Fig. 7a,b). This indicated that transcriptomic differences between MB+ 
and MB- groups were not due to a genetic founder effect within our breeding 
program. Collectively, these data indicate that the MB+/- transcriptomic differences 
were genuinely reflective of two phenotypic subsets of young TDP-43Q331K/Q331K mice. 
TDP-43Q331K mice demonstrate age-related deterioration of cortical 
transcriptomes with altered expression and splicing of other ALS-linked genes
Ageing is the greatest known risk factor for sporadic ALS-FTD. To determine the 
effects of ageing on TDP-43Q331K mice we performed a frontal cortical RNASeq study
in 20-month-old mice (Fig. 8a,b,e,f, Supplementary Fig. 7a,b). Comparison of wild-
type and mutant mice revealed transcriptomic differences that partly overlapped with 
the 5-month-old dataset (Fig. 8c,d,g,h). Significantly, aged mutant mice still 
demonstrated a gain of function of TDP-43, increased retention of Mapt exons 2 and 
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3, and reduced Nek1 and Pvalb expression. However, a broader range of 
transcriptomic changes was seen, further implicating inhibitory interneuronal
disturbances, including downregulation of Sirt1 and Pgc-1α, which encode proteins 
involved in Pvalb transcription, and downregulation of GAD1/GAD67, which encodes 
the GABA synthetic protein glutamate decarboxylase (Supplementary Table 1). 
Aged mice also demonstrated downregulation of Tbk1 (encoding Tank binding 
protein kinase 1) (Fig. 8d), loss of function mutations of which cause ALS and 
FTD34,35. Several other ALS-FTD-linked genes also demonstrated significant 
downregulation, including Chmp2b, mutations of which cause FTD36, Erbb4, 
mutations of which cause ALS37, the ALS risk-linked gene Epha4a38, and the TDP-43 
nuclear import factor Kpnb140. We also observed altered splicing of ALS-linked genes
Matr341 (decreased exclusion of exon 14, which encodes a zinc finger domain), and
Sqstm142 (Fig. 8h-j, Supplementary Fig. 7f,g). For Sqstm1 two splice variants (major 
and minor) were detected in wild-type and mutant mice, but a third variant was 
present only in mutants. This TDP-43Q331K-specific variant comprises a truncated 7th 
exon and a 2bp frameshift in exon 8 of Sqstm1, which is predicted to introduce a 
premature stop codon with loss of the C-terminal ubiquitin-associated domain of 
sequestosome 1 (Fig. 8j). Furthermore, Gene Ontology and pathway analysis of the 
RNASeq dataset in 20-month-old mice revealed many more significant networks than 
had been identified in 5-month-old TDP-43Q331K mice. Aged mutants demonstrated 
changes in processes classically linked to neurodegeneration, including protein 
ubiquitination, autophagy, and glutamate receptor activity, while KEGG pathway 
analysis highlighted ‘ALS’ and immune pathways (Fig. 8b). These pathways were not 
invoked in young mice (Fig. 4g). Collectively, these observations in aged mutant mice 
validate key transcriptomic findings in young mutants, link aberrant TDP-43 
homeostasis with other key ALS-FTD-linked genes, and indicate age-related 
progressive changes in the cortical transcriptomes of TDP-43Q331K mice. 
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Finally, to identify transcriptomic differences associated with long-term resistance to 
cognitive impairment we performed an MB+/- comparison in aged mice. As most 
aged TDP-43Q331K/Q331K mice had progressed to an MB- state by 20 months, we 
compared TDP-43Q331K/+ mice, which we were able to stratify into MB+ and MB- 
groups. This comparison yielded only 21 differentially expressed genes, and 45 
splicing differences between TDP-43Q331K/+ MB+ and MB- mice, which did not overlap 
with those genes identified in the MB+/- comparison of 5-month-old TDP-43Q331K/Q331K 
mice (Supplementary Fig. 7c-e). This suggests that aged TDP-43Q331K/+ mice are not 
amenable to stratification in the same way as young TDP-43Q331K/Q331K mice, and 
further suggests that modulation of MB+/- genes early in life has the potential to
influence longer-term susceptibility to cognitive impairment secondary to aberrant 
TDP-43 homeostasis. 
Discussion
Here, we show that with a single human disease-linked base change in murine 
Tardbp it is possible to replicate behavioural, pathological and transcriptomic features 
of the ALS-FTD spectrum. Significantly, by creating a model that mimics the human 
mutant state as closely as possible and in the absence of exogenous expression we 
elucidated that the Q331K mutation perturbs TDP-43 autoregulation. This leads to an 
increase in TDP-43 expression (effectively a gain of function defect). Interestingly, 
spinal cords from sporadic ALS patients and from TARDBP mutation carriers 
demonstrate increased TDP-43 mRNA expression, as do human stem cell-derived 
motor neurons with TARDBP mutations43,44. This indicates that TDP-43 misregulation
could underpin the human disease state.
Interestingly, lumbar motor neurons of TDP-43Q331K/Q331K mice demonstrated
17
upregulation of genes that may confer neuroprotection and did not demonstrate TDP-
43 misregulation, both of which might explain why mutant mice did not demonstrate 
significant neuromuscular phenotypes. By contrast, the FTD-like phenotypes in 
mutant mice were more significant. The identification of reduced parvalbumin
expression as a possible cause for cognitive impairment in ALS-FTD is intriguing as 
parvalbumin interneuron loss has been observed in sporadic ALS and FTD26. As
parvalbumin interneurons are GABAergic a reduction in their number could increase
activity of cortical projection neurons with excitotoxic consequences. Early 
interneuronal dysfunction may have analogous consequences in the spinal cord and 
is suggested by our observation that TDP-43 autoregulation is perturbed in the spinal 
cord, but not in motor neurons.
That TDP-43Q331K mice demonstrate a specific increase in inclusion of Mapt exons 2 
and 3 is of great interest as 2N tau oligomers appear to have a greater ability to 
provoke tau aggregation than 0N and 1N isoforms30, and inclusion of exon 2 and 3 
influence subcellular localisation and protein-protein interactions of tau45. 
Furthermore, in humans the H2 Mapt haplotype is associated with a greater inclusion 
of Mapt exon 3 and is associated with an earlier age of onset in FTD46,47. Although we 
did not observe clear disturbances of total tau localisation in TDP-43Q331K mice, more 
detailed analyses to identify specific tau isoforms are warranted. Our identification of 
a mechanistic link between TDP-43 and Mapt adds to growing evidence that ALS-
FTD is characterised by both TDP-43 and tau pathology48. Furthermore, 
transcriptomic analysis of aged TDP-43Q331K mice elucidated changes in other ALS-
FTD linked genes. Collectively, these findings emphasise a central role for TDP-43 in 
neurodegeneration.
Finally, we observed phenotypic heterogeneity among mutant mice with the same 
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genotype and identified distinct transcriptomic profiles corresponding to differing 
phenotypes. This transcriptomic dataset contains genes already implicated in 
neurodegeneration, including Arid4a12, and Atxn231. The unbiased discovery of Atxn2
downregulation as a hit in our model is consistent with observations validating Atxn2
knockdown as a therapeutic approach for ALS-FTD32. Our data suggest a delicate 
balance in the transcriptome of the brain, which is metastable and can influence 
disease onset or progression. Identifying the environmental factors that influence this 
balance is a priority in future studies. Indeed, the strong representation of DNA 
methylation and chromatin modelling genes in the MB+/- comparison suggests a 
critical role for epigenetic influences in determining disease susceptibility. Genes with 
roles in protein translation and oligodendrocyte biology including myelination also 
feature in our list of putative disease modifiers, and it is encouraging that both these 
pathways have roles in neurodegenerative disease49,50. Our wider list of potential 
modifiers of disease is composed of over 450 gene-expression and splicing changes 
that are associated with improved behaviour in TDP-43Q331K/Q331K mice. We conclude 
that this list contains additional novel suppressors of neurodegeneration that will help 
direct efforts towards developing treatments for ALS-FTD.
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Figure 1. CRISPR mutagenesis, ACBM characterisation and breeding ratios of TDP-43Q331K mice
(a) Chromatograms from the patient originally identified with the Q331K mutation and CRISPR/CAS9 knock-in 
founder mouse #52. Bases are given above the chromatograms and amino acids coded are given below. The 
mutation is highlighted with the red arrow.
(b) SapI restriction enzyme digestion of 1000 bp PCR products across the mutation site from representative
genotyping of wild-type, TDP-43Q331K/Q331K, and TDP-43Q331K/+ mice.
(c) Automated continuous behavioural monitoring (ACBM) of 4-month-old mice (n = 10 mice per genotype; 5 
males and 5 females). Significantly altered behaviours are displayed: walking: interaction P<0.0001; hanging: 
interaction P=0.002; rearing: interaction P=0.038; eating-by-hand: genotype P=0.008; repeated measures two-
way ANOVA.
(d) Walking behaviour as assessed by ACBM in 7.5-month-old male and female mice (n = 5 mice per 
genotype). Walking male: interaction P<0.0001; walking female: interaction P=0.334; repeated measures two-
way ANOVA. 
(e) Ratios of mice genotyped at 10 days (all of which were successfully weaned) broken down by gender. 
Female (χ2=2.311, d.f.=2, P=0.315), Male (χ2=7.612, d.f.=2, P=0.022); Chi square test.
Error bars represent mean ± s.e.m.
Figure 2. Motor impairment, hyperphagia and spinal motor neuronal transcriptomic changes in mutant mice
(a) Rotarod and (b) weights of Cohort 1 mice (n = 14 wild-type, 13 TDP-43Q331K/+ and 13 TDP-43Q331K/Q331K 
mice). (a) Pairwise comparisons: wild-type vs. TDP-43Q331K/+: P=0.014 (*); wild-type vs. TDP-43Q331K/Q331K: 
P=0.0024 (**). (b) Pairwise comparisons: wild-type vs. TDP-43Q331K/+: P=0.002 (**); wild-type vs. TDP-
43Q331K/Q331K: P=0.0002 (***). 
(c) Weekly food consumption over 9 weeks (n = 2 cages per genotype). Comparison: Genotype: P=0.047(*).
(d) Rotarod of weight-matched Cohort 2 mice (n = 16 wild-type, 13 TDP-43Q331K/+ and 15 TDP-43Q331K/Q331K 
mice). 
For (a-d) repeated measures two-way ANOVA followed by Holm-Sidak post-hoc test for pairwise 
comparisons. 
(e) Nissl-stained lumbar motor neurons of 5-month-old mice. Representative images shown. Scale bar, 40
μm.
(f) Quantification of lumbar motor neurons (n = 4 mice per genotype). Comparison: P=0.089 (ns); unpaired t 
test. 
(g) Examples of isometric twitch force recordings during graded nerve stimulation of FDB muscles from 
representative wild-type and TDP-43Q331K/Q331K mice. Each increment corresponds to recruitment of motor 
units of successively higher electrical threshold (n = 5 mice per genotype).
(h) MA plot and (i) hierarchical clustering of significantly differentially expressed genes (DEGs) in laser-
captured motor neurons. In (h) blue dots indicate significant changes, red dots indicate intensity hits. In (i) 
Genes Aox1 and Agrin are labelled. Comparison: DESeq2 wild-type v TDP-43Q331K/Q331K
(j) Immunohistochemistry for AOX1. Representative images from a 5-month-old wild-type mouse shown.
Scale bars, 10μm motor neuron, 100μm ventral root.
(k) AOX1 immunofluorescence in lumbar motor neurons. Comparison: P=0.433 (ns); unpaired t test.
For (h-k) n = 4 mice per genotype.
All error bars denote mean ± s.e.m.
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Figure 3. Cognitive testing indicates executive dysfunction, memory impairment and phenotypic heterogeneity 
in mutant mice
(a) Schematic for the 5-choice serial reaction time task (5-CSRTT).
(b) Sessions required to reach performance criteria for 5-CSRTT (n = 16 per genotype). Pairwise 
comparisons: wild-type vs. TDP-43Q331K/+: P=0.083 (ns); wild-type vs. TDP-43Q331K/Q331K: P=0.004 (**).
(c) 5-CSRTT at 6 months of age (n = 15 wild-type, 16 TDP-43Q331K/+, 15 TDP-43Q331K/Q331K mice). Baseline 
session genotype effects: accuracy: P=0.109; omission: P=0.283). Stimulus duration (SD) probe test genotype 
effects: accuracy: P=0.833; omission: P=0.077 (ns); SD effect: accuracy and omission: P<0.001; Mixed-
effects model.
(d) 5-CSRTT at 12 months of age (n = 15 wild-type, 16 TDP-43Q331K/+, 16 TDP-43Q331K/Q331K mice). Baseline 
session genotype effects: accuracy: P=0.487; omission: P=0.120. SD probe test genotype effects: accuracy: 
P=0.880; omission: P=0.044 (*); SD effect: accuracy: P<0.0001; omission: P<0.0001; genotype by SD 
interaction: accuracy: P=0.081; omission: P=0.271; Mixed-effects model.
(e) Mean trials completed on an unrestricted fixed-ratio schedule (n = 16 per genotype). 
(f) Mean breakpoint on a progressive-ratio schedule (response increment per trial = 4; n = 16 per genotype). 
(g) Novel object recognition sample and (h) choice phases (n = 8 wild-type, 9 TDP-43Q331K/+, 8 TDP-
43Q331K/Q331K mice). For (h) 1 min delay pairwise comparisons: wild-type vs. TDP-43Q331K/+: P=0.158 (ns); wild-
type vs. TDP-43Q331K/Q331K: P=0.158 (ns); 3 hour delay pairwise comparisons: wild-type vs. TDP-43Q331K/+: 
P=0.014 (*); wild-type vs. TDP-43Q331K/Q331K: P=0.009 (**).
For (b,e,f) one-way ANOVA and (g,h) two-way ANOVA, all followed by Holm-Sidak post-hoc tests for pairwise 
comparisons.
(i) Marbles buried in Cohort 1 at 18 months of age (n = 15 wild-type, 13 TDP-43Q331K/+, 14 TDP-43Q331K/Q331K 
mice). Pairwise comparisons: wild-type vs. TDP-43Q331K/+: P=0.009 (**); wild-type vs. TDP-43Q331K/Q331K: 
P<0.0001 (****); Kruskal-Wallis followed by Dunn’s test for pairwise comparisons.
Error bars denote s.e.m. for (c) to (h) and median and interquartile range for (b) and (i).
Figure 4. Perturbed TDP-43 autoregulation and loss of parvalbumin interneurons in mutant mice
(a) Marbles buried by 5-month-old mice. Coloured dots indicate animals used for RNASeq analysis. Yellow 
dots indicate TDP-43Q331K/Q331K littermates (n = 19 wild-type, 19 TDP-43Q331K/+, 17 TDP-43Q331K/Q331K mice). 
Pairwise comparisons: wild-type vs. TDP-43Q331K/+: P=0.028 (*); wild-type vs. TDP-43Q331K/Q331K: P=0.013 (*); 
Kruskal-Wallis followed by Dunn’s test for pairwise comparisons. Error bars represent median and interquartile 
range.
(b) Representative Nissl staining of frontal cortex (layers indicated) (n = 5 wild-type, 6 TDP-43Q331K/Q331K mice). 
Scale bar, 500μm.
(c) Immunohistochemistry for TDP-43 in pyramidal neurons of motor cortex layer V. Representative images 
shown (n = 4 mice per genotype). Scale bar, 20μm.
(d) Immunoblot of fractionated frontal cortical tissue from 5-month-old mice (two biological replicates shown, 
uncropped in Supplementary Fig. 5).
(e) Immunoblot band intensity quantification (n = 4 mice per genotype). Comparison: P=0.007 (**); unpaired t 
test. Error bars denote s.e.m.
(f) MA plot and (g) hierarchical clustering of DEGs (n = 6 wild-type, 6 TDP-43Q331K/+, 8 TDP-43Q331K/Q331K mice) 
in frontal cortex. For (f) blue dots indicate significant changes, red dots indicate intensity hits. Comparison: 
DESeq2 wild-type v TDP-43Q331K/Q331K. For (g) gene ontology (GO) biological process and KEGG pathway 
enriched terms are displayed.
(h) Expression changes for parvalbumin and ALS-FTD linked genes identified by RNASeq. 
(i) Immunohistochemistry for parvalbumin in cortices of 5-month-old mice. Representative images shown.
Scale bar, 250μm.
(j) Quantification of parvalbumin-positive neurons (n = 3 mice per genotype). Comparison: P=0.0003 (***);
unpaired t test. Error bars denote s.e.m.
(k) Immunohistochemistry for TDP-43 in parvalbumin-positive cells. Representative images shown. Scale bar, 
5μm.
(l) TDP-43 expression in parvalbumin-positive cells (n=5 mice per genotype). Comparison by two-way 
ANOVA. Error bars denote s.e.m.
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Figure 5. Splicing analysis indicates TDP-43 misregulation, a gain of TDP-43 function and altered Mapt exon 
2/3 splicing
(a) MA plot and (b) hierarchical clustering of frontal cortical alternative splice events (n = 6 wild-type, 6 TDP-
43Q331K/+, 8 TDP-43Q331K/Q331K mice). Comparison: DESeq2 wild-type v TDP-43Q331K/Q331K. 
(c) Schematic of altered splicing in the 3’UTR of Tardbp. Arrow indicates reduced exclusion of intron 7 of the 
Tardbp transcript in TDP-43Q331K/Q331K relative to wild-type mice.
(d) Quantitative PCR (qPCR) of splicing changes in Tardbp intron 7 (n = 6 wild-type, 6 TDP-43Q331K/+, 8 TDP-
43Q331K/Q331K mice).
(e) Schematic of exon 17b inclusion/exclusion in Sort1. Arrows indicate reduced inclusion of exon 17b in TDP-
43Q331K/Q331K relative to wild-type mice.
(f) qPCR of splicing changes in Sort1 exon 17b (n = 6 wild-type, 6 TDP-43Q331K/+, 8 TDP-43Q331K/Q331K mice). 
(g) Schematic of altered splicing of exons 2 and 3 of Mapt. Arrows indicate increased inclusion of exons 2 and 
3 in the Mapt transcripts of TDP-43Q331K/Q331K relative to wild-type mice. The expanded view of exon 1 to exon 
2 includes a site of TDP-43 binding as detected by iCLIP (iCount pipeline; TDP-43_CLIP_E18-brain).
(h) Schematic of N-terminal Mapt splice variants (0N, 1N and 2N).
(i) qPCR of splicing changes in Mapt exons 2 and 3 (n = 6 wild-type, 6 TDP-43Q331K/+, 8 TDP-43Q331K/Q331K mice). 
2N/0N pairwise comparisons: wild-type vs. TDP-43Q331K/+: P=0.047 (*); wild-type vs. TDP-43Q331K/Q331K: 
P=0.0001 (***); TDP-43Q331K/+ vs. TDP-43Q331K/Q331K: P=0.013 (*). 
(j-k) qPCR of hippocampal splicing changes (n = 4 wild-type, 3 TDP-43Q331K/+, 4 TDP-43Q331K/Q331K mice per 
gender). Pairwise comparisons: Tardbp intron 7 exclusion, male: wild-type vs. TDP-43Q331K/+: P=0.043 (*); TDP-
43Q331K/+ vs. TDP-43Q331K/Q331K: P=0.002 (**); female: wild-type vs. TDP-43Q331K/+: P=0.013 (*); TDP-43Q331K/+ vs. 
TDP-43Q331K/Q331K: P=0.0002 (***); Mapt: 0N, male: wild-type vs. TDP-43Q331K/+: P=0.023 (*); wild-type vs. TDP-
43Q331K/Q331K: P=0.023 (*); TDP-43Q331K/+ vs. TDP-43Q331K/Q331K: P=0.877 (ns); female: wild-type vs. TDP-43Q331K/+: 
P=0.365 (ns); wild-type vs. TDP-43Q331K/Q331K: P=0.324 (ns); TDP-43Q331K/+ vs. TDP-43Q331K/Q331K: P=0.858 (ns); 
1N/0N, male: wild-type vs. TDP-43Q331K/+: P=0.008 (**); TDP-43Q331K/+ vs. TDP-43Q331K/Q331K: P=0.008 (**); 
female: wild-type vs. TDP-43Q331K/+: P=0.077 (ns); TDP-43Q331K/+ vs. TDP-43Q331K/Q331K: P=0.002 (**); 2N/0N, 
male: wild-type vs. TDP-43Q331K/+: P=0.002 (**); wild-type vs. TDP-43Q331K/Q331K: P=0.0001 (***); TDP-43Q331K/+
vs. TDP-43Q331K/Q331K: P=0.151 (ns); female: wild-type vs. TDP-43Q331K/+: P=0.202 (ns).
For (d,f,i-k) P<0.0001 (****). For (d,f,i) one-way and (j,k) two-way ANOVA, all followed by Holm-Sidak post-
hoc tests for pairwise comparisons. 
Error bars denote s.e.m.
Figure 6. TDP-43 misregulation occurs in spinal cords of mutant mice, but not in motor neurons
(a) Schematic detailing lumbar spinal cord (LSC) processing for transcriptomic analysis (LCM, laser capture 
microdissection).
(b) MA plots of lumbar motor neuronal differentially expressed and spliced genes (n = 4 mice per genotype). 
Comparison: DESeq2 wild-type v TDP-43Q331K/Q331K. Blue and red dots indicate significant changes. Green dots 
highlight Tardbp expression, Tardbp intron 7 exclusion and Sort1 exon 17b inclusion, which are not significant
changes.
(c-d) Quantitative PCR of homogenised lumbar spinal cord (n = 4 wild-type, 4 TDP-43Q331K/+, 4 TDP-
43Q331K/Q331K mice). Comparisons as follows:
(c) Tardbp expression: wild-type vs. TDP-43Q331K/+: P=0.103 (ns); wild-type vs. TDP-43Q331K/Q331K: P=0.0008 
(***); TDP-43Q331K/+ vs. TDP-43Q331K/Q331K: P=0.007 (**). Tardbp intron 7 exclusion: wild-type vs. TDP-43Q331K/+: 
P=0.001 (***); wild-type vs. TDP-43Q331K/Q331K: P>0.0001 (****); TDP-43Q331K/+ vs. TDP-43Q331K/Q331K: P=0.002 
(**). Sort1 exon 17b inclusion: P<0.0001 (****).
(d) 0N Mapt. 1N Mapt: wild-type vs. TDP-43Q331K/+: P=0.640 (ns); wild-type vs. TDP-43Q331K/Q331K: P=0.02 (*); 
TDP-43Q331K/+ vs. TDP-43Q331K/Q331K: P=0.03 (*). 2N Mapt. 
(c-d) Comparisons by one-way ANOVA followed by Holm-Sidak post-hoc tests.
Error bars denote s.e.m.
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Figure 7: Phenotypic stratification of transcriptomic data from mutant mice allows the identification of putative 
disease modifiers
(a) Marble-burying in 5-month-old mice prior to sacrifice. MB+ mice bury at or above the median number of 
marbles for the group, and MB- mice bury fewer. Yellow dots indicate TDP-43Q331K/Q331K littermates. 
(b) Marble burying activity of TDP-43Q331K/Q331K littermates as described in (a). 
(c) Hierarchical clustering of DEGs in frontal cortices comparing MB+ and MB- TDP-43Q331K/Q331K mice. Genes 
Atxn2 and Arid4a are highlighted (n = 6 wild-type, 4 MB+ TDP-43Q331K/Q331K and 4 MB- TDP-43Q331K/Q331K mice). 
Comparison: DESeq2 MB+ v MB-. Gene ontology (GO) biological processes and KEGG pathway enriched 
terms are displayed. 
(d) Graphical representation of altered splicing of Mbp. Arrows indicate the altered pattern of splicing in MB+ 
relative to MB- TDP-43Q331K/Q331K mice. 
(e) qPCR of the ratio of Mbp Basic to Mbp Golli  (n = 6 wild-type, 4 TDP-43Q331K/+, 4 TDP-43Q331K/Q331K mice). 
Pairwise comparisons: wild-type vs. MB+: P=0.005 (**); wild-type vs. MB-: P=0.024 (*); MB+ vs. MB-: 
P=0.0003 (***); one-way ANOVA followed by Holm-Sidak post-hoc tests. Error bars denote s.e.m.
(f) Representative marble burying analyses: 4:4, original analysis; 3:3, comparing the three best MB+ and 
three worst MB- mice; 4v4 mixed, one MB- mouse swapped with one MB+ mouse. Number of DEGs identified 
by DESeq2 comparison of MB+ v MB- mice for each comparison is given below. For 3:3, hits common to the 
4:4 stratification are shown in brackets.
Figure 8. TDP-43Q331K mice demonstrate age-related deterioration in cortical transcriptomes with altered 
expression of multiple ALS-linked genes
(a) MA plot and (b) hierarchical clustering of DEGs in frontal cortices at 20 months of age (n = 8 wild-type, 10 
TDP-43Q331K/+, 10 TDP-43Q331K/Q331K mice). For (a) blue dots indicate significant changes, red dots indicate 
intensity hits. Comparison: DESeq2 wild-type v TDP-43Q331K/Q331K. For (b) gene ontology (GO) biological 
processes and KEGG pathway enriched terms are displayed.
(c) Venn diagram highlighting DEGs between wild-type v TDP-43Q331K/Q331K mice that were common to 
analyses in 5 and 20-month-old mice. Known ALS-FTD linked genes within this common subset are 
highlighted in (d).
(e) MA plot and (f) hierarchical clustering of frontal cortical alternative splice events at 20 months of age (n = 
8 wild-type, 10 TDP-43Q331K/+, 10 TDP-43Q331K/Q331K mice). Blue dots indicate significant changes, red dots 
indicate intensity hits. Comparison: DESeq2 wild-type v TDP-43Q331K/Q331K. 
For (a,b,e,f) n = 8 wild-type, 10 TDP-43Q331K/+, 10 TDP-43Q331K/Q331K mice.
(g) Venn diagram highlighting alternative splice events between wild-type v TDP-43Q331K/Q331K mice that are 
common to analyses in 5 and 20-month-old mice. Known ALS-FTD linked genes within this common subset 
are highlighted in (h).
(i) Schematic of Matr3 exon 14 inclusion/exclusion. Arrows indicate increased inclusion of exon 14 in TDP-
43Q331K/Q331K relative to wild type mice.
(j) Schematic of Sqstm1 transcript splice variants. Percentages given indicate the relative amount of each 
variant in TDP-43Q331K/Q331K mice. The TDP-43Q331K-specific variant is undetectable in wild-type mice. 
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Online methods
CRISPR/CAS9 mutagenesis to introduce Q331K mutation
Nucleases were designed to be close to/overlap the desired point mutation. Three CRISPR-
Cas9 nucleases were tested for activity using a GFP reporter plasmid. A 121 bp single-
stranded DNA (ssDNA) oligonucleotide with the point mutation at the mid-point was used as 
a repair template. Guide RNA (gRNA) and a capped Cas9 mRNA were synthesised and 
injected with the donor oligonucleotide into 270 single-cell C57Bl/6J embryos. For sequences 
see Supplementary Table 3. 
Off-targets were predicted using CRISPRseek51. 
Mouse breeding and maintenance
Mouse founder #52 was outcrossed with wild-type C57Bl/6J mice through to the F3 
generation. Three F3 male siblings were bred to wild-type C57Bl/6J mice to generate F4 TDP-
43Q331K/+ mutants, which were intercrossed to generate animals for study.
Power calculations were based on historical rotarod and touchscreen data of wild-type mice. 
This indicated required group sizes of 15 animals per genotype to identify a ~20% difference 
in performance between genotypes. Animals were only excluded from analyses if specified in 
the following methods. 
Mouse breeding was carried out in the UK and USA. ACBM was carried out at the Brown 
University Rodent Neurodevelopment Behaviour Testing Facility. All procedures were 
approved by the Brown University Animal Care and Use Committee. Touchscreen analysis; 
marble burying; object recognition; motor behaviour; food intake and weight measurement; 
pathology; electrophysiology and RNA sequencing all took place in the UK. All experiments 
were conducted in accordance with the United Kingdom Animals (Scientific Procedures) Act 
(1986) and the United Kingdom Animals (Scientific Procedures) Act (1986) Amendment 
Regulations 2012. Animals were housed in cages of up to five animals under a 12 hr
light/dark cycle. 
Genotyping
The Q331K mutation coincidentally introduces a SapI/EarI restriction site, which facilitates 
genotyping (see Supplementary Table 4).
Automated continuous behavioural monitoring
Ten TDP43Q331K/Q331K and 10 wild-type animals (5 female, 5 male of each genotype) from the 
same breeding campaign were obtained from the animal care facility at the University of
Massachusetts Medical School.  Animals were group housed between sessions, but housed 
individually during the 5-day ACBM recording sessions. Cages were monitored with a Firefly 
MV 0.3 MP Mono FireWire 1394a (Micron MT9V022) at 30 frames/s. Cameras were 
connected to a workstation with Ubuntu 14.04 with a firewire card to connect to all cameras. 
For processing by the computer vision system, all videos were down-sampled to 320×240 
pixels. 
The system used for ACBM was modified from that previously described and was re-
implemented in Python and NVIDIA’s CUDNN to speed video analysis subroutines. All video 
analyses were conducted using the Brown University high-performance computer cluster.
The system was retrained using data collected at the Brown Rodent Neuro-Developmental 
Behaviour Testing facility (~20 h of video and 40 animals total). Data were annotated by hand 
for 8 behaviours as previously described (drink, eat, groom, hang, rear, rest, sniff, walk). 
Accuracy was evaluated using by cross-validation. The average agreement with human 
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annotations was 78% for individual behaviour and 83% overall for individual frames. 
Evaluation of the system was also run on a subset of the data collected for the present study, 
which found an overall mean agreement of 71% for individual behaviours and 82% over all 
video frames.
Rotarod
Motor testing was performed using Rotarod (Ugo Basile, Model 7650, Varese, Italy). At least 
24 h prior to testing mice were first trained for 5 min at the slowest speed and then 7 min with 
acceleration. During testing mice were subjected to 7 min trials with acceleration from 3.5 to 
35 rpm. In each session mice were tested 3 times with a trial separation of 30 min. The 
latency to fall (maximum 420 s) for each mouse was recorded and mean values for each 
mouse calculated. An individual mouse recording was excluded if it fell off the rod while 
moving backwards, accidentally slipped or jumped off at slow speed. Two consecutive 
passive rotations were counted as a fall and the time recorded as the end point for that 
mouse. Mouse weights were recorded immediately after completion of rotarod testing. All 
testing was conducted by operators who were blind to genotype and in a randomised order.
Feeding 
Cages containing either two or three mice of the same genotype were topped up with 400g of 
food on Monday mornings. The following Monday the surplus food in the hopper together 
with any obvious lumps of food in the cage was removed and weighed. The difference from 
400g was calculated and recorded as the total food consumed in seven days. This was 
normalised to the number of mice in a given cage. Weekly consumption was calculated for 9 
consecutive weeks. Mice were 12 months of age when recording commenced. All testing was 
conducted while blind to genotype and in a randomised order.
Touchscreen studies 
48 male mice (n = 16 per genotype) were housed in groups of 2-5 per cage under a 12 hr
light/dark cycle (lights on at 7:00pm). Testing was conducted during the dark phase. To 
ensure sufficient levels of motivation, animals were food-restricted to ~85-90% of free-fed 
weights by daily provision of standard laboratory chow pellets (RM 3; Special Diet Services, 
Essex, UK). Drinking water was available ad libitum.  
Experiments were performed in standard mouse Bussey-Saksida touchscreen chambers
(Campden Instruments Ltd, Loughborough, UK). The reward for each correct trial was 
delivery of 20 μL of milkshake (Yazoo Strawberry milkshake®; FrieslandCampina UK, 
Horsham, UK). The chambers are equipped with infrared activity beams (rear beam = 3 cm 
from magazine port and front beam = 6 cm from screen) to monitor locomotor activity. 
Following two days of habituation to touchscreen chambers, mice underwent pretraining and 
training. Briefly, mice were first trained to touch the correctly lit stimulus in return for a food 
reward, and to initiate a trial by poking and removing their nose from the magazine. Finally, 
mice were discouraged from making responses at non-illuminated apertures by a 5 s time-out 
period during which the chamber was illuminated. Investigators were blind to genotype. 
5-choice serial reaction time task (5-CSRTT)
Upon completion of training at 2 s stimulus duration (baseline), mice were tested on 4 
sessions of decreasing stimulus durations (2.0 s, 1.5 s, 1.0 s, 0.5 s) pseudo randomly within 
a session. Animals that had not reached the criterion (> 80% accuracy, < 20% omissions in 
two consecutive sessions in baseline training before entering the probe test, N = 1 in the first 
probe test) or whose body weights were below 80% of free-feeding weight (N = 1 in the first, 
and N = 1 in the second probe test) were excluded. 
Fixed-ratio (FR) and progressive-ratio (PR) schedule
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FR and PR were conducted as described elsewhere52. When performance stabilised on FR5 
(completion of 30 trials within 20 min), all mice were tested on two sessions of an unrestricted 
FR5, which allowed an unlimited number of trials in 60 min. Next, animals underwent 3 
sessions of PR4, in which animals should emit a progressively increasing number of 
responses (i.e. 1, 5, 9, 13, …) in each subsequent trial to obtain a single reward. PR session
terminated following either 60 min or 5 min of inactivity. Breakpoint, the number of responses 
made to obtain the reward in the last completed trial, was recorded as an index of motivation.
Object recognition
The novel object recognition task was conducted as described elsewhere53 in a randomised 
order with the operator blind to genotype and under dimmed white light. Six-month-old male 
mice (n = 8-9 per genotype) were randomly chosen from Cohort 2. Mice were habituated to a 
Y-maze for 5 min. One day later mice were reintroduced to the Y-maze, which now contained 
two identical objects in each arm. Exploration time for each object over a 5 min period was 
recorded (sample phase). Mice were then removed from the maze and one of the objects 
replaced with a novel object. After a delay of 1 min or 3 h mice were reintroduced to the 
maze (choice phase) and the time spent exploring each object over a 5 min period was 
recorded. The memory for the familiar object was expressed as a discrimination ratio
(difference in exploration of the novel and familiar objects divided by the total object 
exploration time). 
Marble burying
All testing was conducted in the morning and blind to genotype. Cages of size 39.1cm x 
19.9cm x 16.0cm height (Tecniplast) were used. Fresh bedding material (Datesand, grade 6) 
was placed into each cage to a height of ~6cm. Ten glass marbles (1cm) were placed evenly 
across the bedding. Ten cages were prepared in a single round. One mouse was placed in 
each of the cages and the lids replaced. Mice were left undisturbed for 30 min under white 
light. Mice were then removed and the number of marbles buried by at least two thirds was 
scored. Cages were reset using the same bedding material to test another 10 mice. In 
stratifying mice prior to frontal cortical RNAseq, animals were tested twice, three days apart 
to identify those that consistently buried high or low numbers of marbles. 
Repeat behavioural studies
Cohort 1 mice underwent rotarod, weight, feeding and marble testing all under a standard 
light/dark cycle (lights on at 7:00am for 12h). Cohort 2 mice underwent all touchscreen, object 
recognition and rotarod studies under a reverse light/dark cycle. 
Pathological studies
Mice were culled by cervical dislocation, decapitated and tissues processed as follows. 
Brains
Right hemispheres were processed for RNA and/or protein extraction (see below). Left 
hemispheres were immersion fixed in 4% paraformaldehyde (PFA) at 4°C for 24 h, washed in 
PBS, cryoprotected in 30% sucrose in PBS at 4°C, embedded and frozen in M1 matrix 
(Thermo Fisher Scientific) on dry ice and sectioned coronally at 16 μm thickness on a 
cryostat (Leica Biosystems). Sections were mounted on Superfrost Plus charged slides 
(Thermo Fisher Scientific), allowed to dry overnight and stored at -80°C.
Spinal cords
Vertebral columns were dissected from culled mice, immersion fixed in 4% PFA at 4°C for 48 
h, washed in PBS and dissected to extract spinal cords and nerve roots. The lumbar 
enlargement was sub dissected, cryoprotected in 30% sucrose at 4°C, embedded in M1 
matrix in a silicon mould, frozen on dry ice and sectioned at 16 μm thickness onto charged 
slides, briefly air dried and stored at -80°C.
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Antigen retrieval and immunostaining
Sections were thawed at R/T and briefly rinsed in distilled water. Antigen retrieval was 
performed by heating slides for 20 min at 95°C in antigen unmasking solution, Tris-based 
(Vector laboratories). Sections were cooled to R/T, washed in distilled water, and blocked 
and permeabilised in a solution containing 5% bovine serum albumin (BSA), 0.1% Triton X-
100 and 5% serum (specific to secondary antibody species used) for 1 h at R/T. Slides were 
incubated with primary antibody for 2 h at R/T or 4°C overnight in 5-fold diluted blocking 
buffer. Secondary antibodies were applied for 1 h at R/T (Alexa Fluor conjugated, Thermo 
Fisher Scientific; 1:500 in diluted block). Sections were counterstained and mounted with 
VECTASHIELD with DAPI (Vector labs) hard-set. Alexa Fluor 568 conjugated secondary 
antibodies were false coloured magenta (ImageJ 1.15j).
To quantify parvalbumin-positive neurons, parvalbumin stained sections were imaged on a 
Nikon Ti-E live cell imager. Images were acquired using a Plan Apo lambda 10x objective 
with a final image dimension of 4608 x 4608 with 2x2 binning, stitched (NIS-Elements) and 
analysed (ImageJ 1.15j) blind to genotype. For each mouse, matching sections through the 
frontal cortex from Bregma 2.8 mm to 0.74 mm were analysed with a total of 10 sections 
quantified for 3 wild-type and TDP43Q331K/Q331K mice. Images were converted to greyscale and 
thresholded to produce a binary image. Consistent regions of interest were drawn around the 
cortex using the polygon selection tool and the ‘analyse particle’ function used to count cells. 
To investigate TDP-43 in parvalbumin-positive neurons, sections were costained with 
antibodies against TDP-43 and parvalbumin and imaged using a Zeiss LSM 780, 
AxioObserver with a Plan-Apochromat 63x/1.40 Oil DIC M27 objective running Zen system 
software. Data analysis (ImageJ 1.15j) and imaging was carried out blind to genotype. For 
each cell, a maximum intensity projection of Z stacks was created and regions of interest 
were drawn around the nucleus and the cytoplasm using the polygon selection tool. Area, 
integrated density and mean grey value measurements were taken for the cytoplasm and 
nucleus, together with a background reading. Corrected total fluorescence for a region of 
interest was calculated as:
CTF = Integrated Density - (Area region of interest x background fluorescence)
Corrected fluorescence was recorded for at least 10 cells per mouse in matched sections 
corresponding to Bregma 1.18 mm (The Mouse Brain, compact third edition, Franklin and 
Paxinos).
To quantify AOX1 fluorescence in lumbar motor neurons, sections were costained with 
antibodies against AOX1 and neurofilament heavy and imaged on a Nikon Ti-E live cell 
imager with a Plan Apo VC 20x DIC N2 objective with a final image dimension of 1024 x 1022 
pixels and 2x2 binning. Data analysis (ImageJ 1.15j) and imaging were carried out blind to 
genotype. Corrected fluorescence was recorded for at least 29 cells per mouse. 
TDP-43 immunostaining in spinal cord and brain were imaged using a Nikon Ti-E live cell 
imager and a Plan Apo VC 100x Oil objective with a final image dimension of 1024 x 1024 
pixels with 2x2 binning. Images are a maximum intensity z-stack created using ImageJ 1.15j 
with a z-step of 0.2µm.
Tau immunostaining in cortex was imaged using a Zeiss LSM 780, AxioObserver with a Plan-
Apochromat 63x/1.40 Oil DIC M27 objective running Zen system software. Images are a 
maximum intensity z-stack created using ImageJ 1.15j. 
For list of primary antibodies see Supplementary Table 5.
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Nissl staining of spinal cord and brain
Sections were thawed at R/T, washed in distilled water then stained with cresyl etch violet 
(Abcam) for 5 min, briefly washed in distilled water, dehydrated in 100% ethanol, cleared in 
xylene, mounted (Permount, Fisher) and dried overnight at R/T. Images were taken on a 
Zeiss Axio Observer.Z1 running Axiovision SE64 release 4.8.3 software. Cortical images 
were taken with an EC Plan-Neofluar 5x/0.16 M27 objective with a total area of 4020 x 2277 
pixels auto stitched within the software. Spinal cord images were acquired with an LD Plan-
Neofluar 20x/0.4 korr M27 objective with an image size of 1388 x 1040 pixels. 
Lumbar spinal motor neuron quantification 
Motor neurons were quantified as described elsewhere54. Briefly, large motor neurons 
(diameter >20 μm) in the ventral horn were counted blind to genotype in 18 sections from the 
lumbar L3-5 levels of each animal. 
Cellular quantification in brain
Data analysis using ImageJ 1.15j and imaging was carried out blind to genotype. For total 
frontal cortical area, matching sections through the frontal cortex from Bregma 2.8 mm to 
0.74 mm were selected with a total of 10 sections quantified for six wild-type and six 
TDP43Q331K/Q331K mice. Matching regions of interest were drawn around the cortex and the 
area quantified using the measure function. To count cells within cortical sub regions, 
matching sections based on Bregma references were identified. Images were converted to 
greyscale and thresholded to produce a binary image. Consistent regions of interest were 
drawn around the cortex and the ‘analyse particle’ function used to count cells. A minimum 
size of 10 pixel units ensured that intact cells were counted and results were displayed with 
the overlay option selected. 
Western blotting
Brain tissues were weighed to ensure equal amounts of starting material between 
samples, thawed on ice and processed using a modified fractional protocol55. Briefly, 
tissue was sequentially homogenised and centrifuged using buffers A [NaCL 150 mM, 
HEPES (pH 7.4) 50mM, digitonin (Sigma, D141) 25 μg/mL, Hexylene glycol (Sigma, 
112100) 1 M, protease inhibitor cocktail (Sigma, P8340), 1% v:v] and B [same as buffer 
A except Igepal (Sigma, I7771) 1% v:v is used in place of digitonin] to extract 
cytoplasmic and membrane fractions respectively. The subsequent pellet was sonicated
in 1% sarkosyl buffer containing 10μM Tris-Cl (pH 7.5), 10μM EDTA, 1M NaCl and 
centrifuged (14,000g for 30min at 4°C). The supernatant was taken as the nuclear 
fraction. Protein lysates were quantified (bicinchoninic acid protein assay, Pierce), 
electrophoresed in 4-12% or 12% SDS polyacrylamide gels, wet transferred to PVDF 
membranes, blocked with a 50:50 mixture of Odyssey PBS blocking buffer and PBS 
with 0.1% Tween20 for 1 h at R/T and then probed with primary antibodies at 4°C 
overnight. Secondary antibodies were either fluorescently tagged for Odyssey imaging, 
or HRP tagged for ECL visualisation. Western blot band intensities were quantified 
using Fiji (ImageJ; Version 2.0.0-rc-54/1.51h; Build: 26f53fffab) using the programs gel 
analysis menu option in 8-bit greyscale. Quantification was carried out by an 
independent user blind to genotype.
For list of primary antibodies see Supplementary Table 5.
Muscle histology 
The right gastrocnemius was dissected, fixed in 4% PFA at R/T, washed in PBS for 10 min 
(x2) and cryoprotected and stored in 30% sucrose with 0.1% azide. Tissues were placed in a 
silicone mould with M1 matrix,and frozen on dry ice. Longitudinal cryosections (50 μm) were 
mounted onto slides (Superfrost Plus), air dried at R/T for 5 min and stored at -80°C.
32
To stain neuromuscular junctions (NMJs), slides were brought up to R/T and incubated in 
blocking solution (2% BSA, 0.2% Triton X-100, 0.1% sodium azide) for 1 h. Primary 
antibodies against βIII-tubulin (rabbit polyclonal, Sigma T2200) and synaptophysin (mouse 
monoclonal, Abcam ab8049) were applied at 1:200 dilution in blocking solution. Sections 
were incubated at R/T overnight. Sections were washed in PBS (x3) and incubated for 90 
min with mouse and rabbit Alexa488-conjugated secondary antibodies (Thermo Fisher 
Scientific) diluted 1:500 in blocking solution together with TRITC-conjugated alpha 
bungarotoxin (Sigma, T0195) 10 μg/ml. Sections were washed in PBS and coverslipped
(VECTASHIELD hardset). Confocal Z-stacks were obtained using a Zeiss LSM 780, 
AxioObserver with a Plan-Apochromat 20x/0.8 M27 objective running Zen system software 
blind to genotype.
For succinate dehydrogenase (SDH) staining, the left gastrocnemius was dissected, flash 
frozen in isopentane in liquid nitrogen and stored at -80°C until use. Frozen sections of 12 
μm were prepared and stained using a modified version of a previously described method56. 
Briefly, sections were stained with freshly prepared SDH staining solution at 37°C for 3 min, 
washed through saline, acetone and ethanol solutions, cleared in xylene and mounted 
(Permount). Images were taken using an Olympus BX41 light microscope (10x objective) with 
Q Capture Pro 6.0.
Quantification of NMJ Innervation
NMJs from flattened z-stacks of muscle were analysed (ImageJ; Version 2.0.0-rc-54/1.51h; 
Build: 26f53fffab) blind to genotype. Brightness and contrast thresholds were set to optimise 
the signal-to-noise ratio of the presynaptic staining (anti-tubulin and anti-synaptophysin).  
Innervated NMJs were defined as having observed overlap of staining for pre- and post- 
synaptic elements. Denervated NMJs were defined as alpha-bungarotoxin signal in the 
absence of pre-synaptic staining. A small percentage (~5% in each genotype) of NMJs could 
not be scored and were excluded from this analysis. 
Neuromuscular electrophysiology
Isolated FDB-tibial nerve preparations were mounted in an organ bath in HEPES-buffered 
MPS of the following composition (mM): Na+ (158); K+ (5); Ca2+ (2); Mg2+ (1); Cl- (169); 
glucose (5); HEPES (5); pH 7.2-7.4, and bubbled with air or 100% O2 for at least 20 min.  The 
distal tendons were pinned to the base of a Sylgard-lined recording chamber and the 
proximal tendon connected by 6/0 silk suture to an MLT0202 force transducer (AD 
Instruments, Oxford, UK). The tibial nerve was aspirated into a glass suction electrode and 
stimuli (0.1-0.2 ms duration, nominally up to 10V) were delivered via a DS2 stimulator 
(Digitimer, Welwyn Garden City, UK) triggered and gated by an AD Instruments Powerlab
26T interface. Force recordings were captured and digitised at 1 kHz using the Powerlab
interface and measured using Scope 4 and Labchart 7 software (AD Instruments) running on 
PC or Macintosh computers. For motor unit recordings, the stimulating voltage was carefully 
graded from threshold to saturation, to evoke the maximum number of steps in the twitch 
tension record. Motor unit number estimation (MUNE) was performed by inspection, counting 
the number of reproducible tensions steps, and by extrapolation between the average twitch 
tension of the four lowest threshold motor units and the maximum twitch tension. For tetanic 
stimulation, trains of stimuli, 1-5 s in duration were delivered at frequencies of 2-50 Hz. To 
measure muscle fatigue, 50 Hz stimulus trains, 1 s in duration were delivered every five 
seconds for about a minute. A fatigue index was calculated as the time constant of the best 
fitting single exponential to the decline of the maxmimum tetanic force.  
Brain RNA isolation
Frontal cortices and hippocampi were subdissected in RNase free conditions (RNaseZap, 
Sigma Aldrich) from right hemispheres of freshly culled mice and flash frozen until further 
use. For RNA extraction tissue was thawed directly in TRIsure reagent (Bioline) and RNA 
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isolated following manufacturer’s instructions. RNA was purified (RNeasy kit, Qiagen) with on-
column DNase treatment and analysed on an Agilent 2100 Bioanalyzer. 
Spinal motor neuron laser capture microdissection
Mice were culled by cervical dislocation and decapitation. Lumber spinal cord was rapidly 
dissected taking care to avoid RNase-exposure, embedded in pre-cooled M1 embedding 
matrix (Thermo) in a silicone mould and flash frozen in isopentane on dry ice. Samples were 
stored at -80°C until use. Transverse cryosections (14 μm) were taken through the lumbar 
enlargement and placed onto PEN membrane glass slides (Zeiss) that were kept at -20°C 
during sectioning. One spinal cord was processed at a time. ~50 sections were taken per 
mouse and placed onto two PEN slides. Slides were immediately stained in the following 
RNase-free, ice-cold solutions (each for 1 min): 70% ethanol, water (with gentle agitation), 
1% cresyl violet in 50% ethanol, 70% ethanol, 100% ethanol (with gentle agitation), 100% 
ethanol (with gentle agitation). Slides were dabbed onto tissue paper to remove excess 
ethanol, air-dried for 1 min and taken for immediate microdissection (Zeiss PALM 
Microbeam). Cells were cut at x40 magnification, keeping laser power to a minimum. Motor 
neurons were identified by location and diameter >30 μm. ~120 cells were captured per
mouse into Adhesive Cap 500 tubes (Zeiss). RNA was extracted using the Arcturus PicoPure
kit (Thermofisher). 1 ul of RNA was run on an RNA 6000 Pico chip on an Agilent 2100 
Bioanalyzer to evaluate RNA quality. 1ng of RNA was used as input for cDNA library 
preparation.
Spinal motor neuron cDNA and library preparation
Library preparation for sequencing on an Illumina HiSeq2500 sequencer was carried out 
using the SMART-seq v4 Ultra low Input RNA kit (Clontech) following the manufacturer’s 
instructions. All steps were carried out on ice unless otherwise specified. Reverse 
transcription, PCR cycles and incubation steps utilised a BioRad T100 Thermal Cycler. 
Amplification of cDNA by LC PCR used a 10-cycle protocol. After bead purification, cDNA
library concentration was measured (High Sensitivity DNA kit, Agilent Technologies). 
Sequencing libraries were generated using the Nextera XT DNA Library Prep Kit (Illumina) 
using 150 pg cDNA as input following the manufacturer’s instructions with the following 
modification. Following library amplification and bead purification the final fragment size was 
analysed and libraries quantified using the Universal KAPA Library Quantification kit (Kapa
Biosystems) and a Bio-Rad C100 thermal cycler. An equal amount of cDNA was used to pool 
up to four samples, which were sequenced in one lane. Sequencing was carried out to a 
depth of 50 million 100 bp paired-end reads per library.
Frontal cortex RNAseq library preparation
Only RNA samples with RIN >8 were used for sequencing. Libraries were prepared using the 
TruSeq Stranded mRNA kit (Illumina) following the manufacturer’s low sample protocol with 
the following modification. RNA fragmentation time was reduced to 3 min at 94°C to increase 
median insert length. Final libraries were analysed, quantified and sequenced as above.
Bioinformatics pipeline and statistics
FastQ files were trimmed with trim galore v0.4.3 using default settings then aligned against 
the mouse GRCm38 genome assembly using hisat2 v2.0.5 using options --no-mixed and --no-
discordant.  Mapped positions with MAPQ values of <20 were discarded. 
Gene expression was quantitated using the RNA-Seq quantitation pipeline in SeqMonk
v1.37.0 in opposing strand specific (frontal cortex) or unstranded (motor neuron) library mode 
using gene models from Ensembl v67. For count based statistics, raw read counts over 
exons in each gene were used. For visualisation and other statistics log2 RPM (reads per 
million reads of library) expression values were used.
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Differentially expressed genes were selected using pairwise comparisons with DESeq2 with a 
cut-off of P<0.05 following multiple testing correction.
Differential splice junction usage was detected by quantitating the raw observation counts for 
each unique splice donor/acceptor combination in all samples. Initial candidates were 
selected using DESeq2 with a cut-off of P<0.05 following multiple testing correction. To focus 
on splicing specific events hits were filtered to retain junctions whose expression change was 
>1.5 fold different to the overall expression change for the gene from which they derived, or 
which showed a significant (logistic regression P<0.05 after multiple testing correction) 
change in observation to another junction with the same start or end position. 
A secondary intensity filter was applied to DESeq2 hits akin to a dynamic fold-change filter. 
DESeq2 comparisons were between wild-type and TDP43Q331K/Q331K mice or between MB+ 
and MB- mice. Significant expression and splicing changes between wild-type and 
TDP43Q331K/Q331K were used to generate hierarchical cluster plots including TDP43Q331K/+ mice 
to identify patterns of changes across replicates. Significant expression and splicing changes 
between MB+ and MB- mice were used to generate hierarchical cluster plots including wild-
type mice.
GO, KEGG enrichment analysis
The Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 was used 
for functional annotation of gene expression data in addition to the Functional Enrichment 
Analysis tool (FunRich v3.0) (available at:http://funrich.org). Gene ontology (GO) biological 
process (BP) and KEGG pathway enrichment analysis was conducted using DAVID and 
FunRich with a threshold Benjamini-corrected p-value≤0.05.
Spinal cord RNA extraction for qPCR
Tissues were briefly washed in ice cold PBS to remove mounting media, homogenised and 
RNA was extracted as described above for frontal cortices and hippocampi.
Quantatitive PCR
500 ng of RNA was reverse transcribed (QuantiTect Reverse transcription kit, Qiagen) and 
the output volume of 20 μL diluted 10-fold in nuclease free water (Promega). Real-time PCR 
was performed using Brilliant-III Ultra-Fast SYBR (Agilent Technologies) on a Bio-Rad CFX96 
instrument with cycle conditions based on Agilent’s quick reference guide (publication 
number 5990-3057, Agilent Technologies). Reaction specificity was confirmed by melt curve 
analysis and normalised expression (ΔΔCq) calculated using CFX Manager software 3.1 with 
at least four reference genes. 
For qPCR primer sequence see Supplementary Table 6.
Reference genes used were: Ywhaz, Pgk1, Gapdh and Hprt1. KiCqStart SYBR Green 
primers for these reference genes were purchased from Sigma-Aldrich in addition to Tardbp.
Statistical analyses
Statistical analyses were conducted using Prism 6.05 (GraphPad). Graphs were plotted using 
Graphpad or Python. Use of parametric tests required data to be sampled from a Gaussian 
distribution. Homogeneity of variance between experimental groups was confirmed by the 
Browne-Forsythe test for ANOVA and F test for unpaired t-tests. For comparisons between 
genotypes or experimental groups two-tailed, unpaired t-tests or one-way ANOVA were used 
when comparing two or three groups respectively. Multiple comparisons by ANOVA were 
corrected using the Holm-Sidak test. Where the assumptions of one-way ANOVA were 
violated the non-parametric Kruskal-Wallis test was performed followed by Dunn’s multiple 
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comparison test. All statistical comparisons are based on biological replicates unless stated
otherwise. Where technical replication of experiments occurs, this is highlighted in the 
respective method.
Analyses of Rotarod performance, weights and food intake utilised repeated measures two-
way ANOVA. Mice lacking measurements at any timepoint were excluded from analyses. 
Multiple comparisons by two-way ANOVA were corrected using the Holm-Sidak test.
TDP-43 fluorescence in the nuclear and cytoplasmic compartments of parvalbumin positive 
cells and cell counts in multiple regions of the cortex were compared using multiple t-tests. 
Multiple comparisons were corrected using the Holm-Sidak test (alpha = 5%) without 
assuming consistent standard deviation.
Statistical Analysis: ACBM 
The ACBM system characterized each behaviour for every frame of recording and quantified 
the amount of time the mouse was performing a given behaviour for each hour (0-23). These 
data were averaged across five days of recording within each animal and then subject to 
statistical comparison for within-day and between-group analyses. 
Statistical analysis to compare the average time spent performing a given behaviour between 
TDP43Q331K/Q331K and wild-type mice was conducted using repeated measures two-way 
ANOVA, in which the between-subjects variable was genotype and the within-subjects 
variable was circadian hour (0-23). We report main effects of genotype and genotype x 
circadian hour interactions. All statistics were calculated using IBM SPSS Statistics 24, alpha 
= 0.05.
Statistical analyses: Touchscreens
Data analyses for touchscreen and object recognition tasks were conducted using R version 
3.3.1. Mixed-effects models were used to identify the main effects of genotype or task 
conditions (i.e., stimulus duration in 5-CSRTT or delay in object recognition task) and 
interactions between these factors. Between-genotype differences in sessions to criteria, FR, 
and PR outcomes were analysed by one-way ANOVA with Holm-Sidak post hoc test.
Additional statistical information
See Supplementary Table 7.
Randomisation
The order and genotype of animals and samples tested was randomized by one operator 
before subsequent experimental studies were conducted by a second investigator.
Reproducibility
Life Science Reporting Summary is available online. 
Data availability
The authors will make all data available to readers upon request. RNAseq data have been 
deposited are available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?accGSE99354.
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